

# Vanna Chiarion Sileni

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2008230/vanna-chiarion-sileni-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

227  
papers

33,594  
citations

61  
h-index

183  
g-index

237  
ext. papers

41,551  
ext. citations

8.5  
avg, IF

6.46  
L-index

#	Paper	IF	Citations
227	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.. <i>Journal of Translational Medicine</i> , <b>2022</b> , 20, 159	8.5	1
226	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , <b>2022</b> ,	40	18
225	Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study. <i>Life</i> , <b>2022</b> , 12, 745	3	
224	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 156-168	7.5	5
223	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Targeted Oncology</i> , <b>2021</b> , 16, 789-799	5	1
222	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2102229	2.2	39
221	Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 627527	5.3	2
220	Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. <i>ESMO Open</i> , <b>2021</b> , 6, 100064	6	8
219	The immune cell landscape of metastatic uveal melanoma correlates with overall survival. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 154	12.8	4
218	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 655-664	21.7	9
217	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 643-654	21.7	58
216	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4737-4745	12.9	8
215	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 574-580	8.7	9
214	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	10
213	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 70	8.5	1
212	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , <b>2021</b> , 152, 116-128	7.5	2
211	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1926-1934	7.5	1

210	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival <b>2021</b> , 9,		7
209	Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143).. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 737842	5.3	4
208	1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. <i>Annals of Oncology</i> , <b>2020</b> , 31, S731-S732 <sup>3</sup>	10.3	3
207	1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial. <i>Annals of Oncology</i> , <b>2020</b> , 31, S734	10.3	5
206	Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 393-402	2.6	
205	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma <b>2020</b> , 8,		19
204	A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 529	5.3	4
203	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 358-372	21.7	49
202	Cost-effectiveness of a melanoma screening programme using whole disease modelling. <i>Journal of Medical Screening</i> , <b>2020</b> , 27, 157-167	1.4	1
201	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3937-3946	2.2	39
200	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1435-1448	10.3	49
199	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1652	5.3	6
198	LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). <i>Annals of Oncology</i> , <b>2020</b> , 31, S1173-S1174	10.3	16
197	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1449-1461	10.3	19
196	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1139-1148	59.2	105
195	Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1465-1477	21.7	140
194	Cholecystectomy during esophagectomy is safe but unnecessary. <i>Acta Chirurgica Belgica</i> , <b>2020</b> , 120, 35-41	4.9	1
193	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 289	8.5	13

192	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , <b>2019</b> , 119, 168-178	7.5	32
191	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1535-1546	59.2	1260
190	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 626-636	59.2	489
189	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. <i>Cancer Science</i> , <b>2019</b> , 110, 1552-1563	6.9	8
188	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 701-710	21.7	23
187	Reply to E. Hindle and K.R. Hess. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1356-1358	2.2	1
186	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> , <b>2019</b> , 19, 772	4.8	17
185	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , <b>2019</b> , 119, 1-10	7.5	79
184	PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. <i>Cancer Medicine</i> , <b>2019</b> , 8, 6036-6048	4.8	16
183	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , <b>2019</b> , 119, 97-106	7.5	27
182	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , <b>2019</b> , 121, 144-153	7.5	19
181	The density and spatial tissue distribution of CD8 and CD163 immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors <b>2019</b> , 7, 308		32
180	Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600E mutant unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9507-9507	22.7	4
179	Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , <b>2019</b> , 29, 527-532	3.3	5
178	Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. <i>Melanoma Research</i> , <b>2019</b> , 29, 89-94	3.3	4
177	An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 175-185	7.5	7
176	Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 99-105.e5	4.5	11
175	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 187-194	13.4	173

174	Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy. <i>Journal of Oncology Pharmacy Practice</i> , <b>2019</b> , 25, 787-792	1.7	4
173	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 510-520	21.7	123
172	Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 1332-1340	6.1	13
171	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , <b>2018</b> , 2, CD011123	5.2	85
170	Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 94	8.5	73
169	Time to diagnosis in esophageal cancer: a cohort study. <i>Acta Oncologica</i> , <b>2018</b> , 57, 1179-1184	3.2	10
168	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 603-615	21.7	451
167	Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines. <i>Acta Dermato-Venereologica</i> , <b>2018</b> , 98, 218-224	2.2	14
166	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9502-9502	2.2	43
165	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9504-9504	2.2	19
164	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9590-9590	2.2	7
163	Esophageal Cancer Clinical Presentation: Trends in the Last 3 Decades in a Large Italian Series. <i>Annals of Surgery</i> , <b>2018</b> , 267, 99-104	7.8	16
162	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3441-3449	2.2	137
161	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. <i>Scientifica</i> , <b>2018</b> , 2018, 5036213	2.6	8
160	Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients. <i>Cancers</i> , <b>2018</b> , 10,	6.6	13
159	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1480-1492	21.7	680
158	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1315-1327	21.7	291
157	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 393-403	21.7	69

156	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 54, 34-42	14.4	39
155	Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. <i>Journal of Chemotherapy</i> , <b>2017</b> , 29, 245-251	2.3	5
154	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders analysis. <i>European Journal of Cancer</i> , <b>2017</b> , 79, 176-184	7.5	23
153	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1631-1639	10.3	361
152	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 45-55	7.5	114
151	Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 863-873	21.7	389
150	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 611-622	21.7	306
149	Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. <i>Annals of Oncology</i> , <b>2017</b> , 28, v442	10.3	2
148	A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. <i>European Journal of Dermatology</i> , <b>2017</b> , 27, 482-486	0.8	6
147	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3807-3814	2.2	264
146	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1813-1823	59.2	778
145	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1824-1835	59.2	1178
144	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1345-1356	59.2	2030
143	CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL. <i>International Journal of Technology Assessment in Health Care</i> , <b>2017</b> , 33, 199-205	1.8	2
142	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 80-91	7.5	55
141	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1929-1936	12.9	181
140	Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 264-273.e2	4.5	32
139	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) <b>2017</b> ,		26



138	Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett's carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy. <i>Oncotarget</i> , <b>2017</b> , 8, 24372-24379	3.3	6
137	Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study. <i>Pharmacogenomics Journal</i> , <b>2016</b> , 16, 266-71	3.5	3
136	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <i>Oncotarget</i> , <b>2016</b> , 5, e1249559	7.2	35
135	A germline predictive signature of response to platinum chemotherapy in esophageal cancer. <i>Translational Research</i> , <b>2016</b> , 171, 29-37.e1	11	14
134	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1845-1855	59.2	870
133	Nivolumab in previously untreated melanoma without BRAF mutation. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 320-30	59.2	3809
132	Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2086-94	7.5	36
131	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 833-40	7.5	60
130	A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. <i>Melanoma Research</i> , <b>2015</b> , 25, 164-8	3.3	29
129	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 522-30	21.7	842
128	Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1191-6	2.2	334
127	12th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN) Rimini (Italy), April 16-19, 2015. <i>Clinical and Translational Imaging</i> , <b>2015</b> , 3, 1-144	2	3
126	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1389-98	21.7	162
125	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. <i>Future Oncology</i> , <b>2015</b> , 11, 1355-62	3.6	4
124	Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 30-9	59.2	1723
123	Development and external validation of a prognostic nomogram for metastatic uveal melanoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120181	3.7	24
122	Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. <i>Melanoma Research</i> , <b>2015</b> , 25, 75-9	3.3	23
121	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 23-34	59.2	5047

120	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , <b>2015</b> , 386, 444-51	4.0	926
119	Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. <i>Radiology and Oncology</i> , <b>2015</b> , 49, 71-4	3.8	22
118	Genetic features of metachronous esophageal cancer developed in Hodgkin lymphoma or breast cancer long-term survivors: an exploratory study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0117070	3.7	5
117	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 118, 109-16	4.8	90
116	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1877-88	59.2	1195
115	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2014</b> , 33, 30	12.8	76
114	Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 116	8.5	130
113	Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 117	8.5	21
112	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1428-1436	10.3	36
111	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 436-44	21.7	206
110	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 121-7	7.5	126
109	Clinical electrochemotherapy for advanced superficial melanoma <b>2014</b> , 35-53		1
108	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. <i>Cancer Investigation</i> , <b>2014</b> , 32, 144-9	2.1	74
107	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 1721-6	8.7	44
106	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. <i>Journal of Chemotherapy</i> , <b>2014</b> , 26, 193-201	2.3	14
105	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , <b>2014</b> ,	5.2	7
104	<sup>18</sup> F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients. <i>Nuclear Medicine Communications</i> , <b>2014</b> , 35, 160-8	1.6	4
103	Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma. <i>Melanoma Research</i> , <b>2014</b> , 24, 413-4	3.3	15



102	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9011-9011	2.2	26
101	Report from the Melanoma Independent Board First Melanoma MIB Conference, 21-22 October 2013. <i>Ecancermedalscience</i> , <b>2014</b> , 8, 440	2.7	1
100	Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?. <i>Journal of Gastrointestinal Surgery</i> , <b>2013</b> , 17, 1375-81	3.3	61
99	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 897-908	7.4	28
98	Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma. <i>Journal of the Neurological Sciences</i> , <b>2013</b> , 335, 210-2	3.2	10
97	Interferon alpha for the adjuvant treatment of cutaneous melanoma. <i>The Cochrane Library</i> , <b>2013</b> , CD008955	9.5	88
96	Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2413-20	2.2	163
95	Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1211-8	2.2	78
94	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2911-5	10.3	102
93	Follow-up of melanoma: a survey of Italian hospitals. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 32-8	4.4	9
92	Surgical management of suspicious melanocytic lesions in Italy. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 18-21	4.4	1
91	Management of small and intermediate congenital nevi: a nationwide survey in Italy. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 7-12	4.4	4
90	Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 22-7	4.4	4
89	Impact of mole mapping in the Italian health system. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 13-7	4.4	2
88	Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2013</b> , 32, 82	12.8	16
87	Surgical treatment of melanoma: a survey of Italian hospitals. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 28-31	4.4	21
86	Diagnostic services for melanoma in Italy. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 3-6	4.4	2
85	Melanoma Task Force (META) Project in Italy: methodology. <i>Dermatology</i> , <b>2013</b> , 226 Suppl 1, 1-2	4.4	17

84	An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9013-9013	2.2	49
83	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9070-9070 <sup>2,2</sup>		6
82	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 41-8	7.4	104
81	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , <b>2012</b> , 380, 358-65	40	2233
80	The cost of unresectable stage III or stage IV melanoma in Italy. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2012</b> , 31, 91	12.8	20
79	Electrochemotherapy for disseminated superficial metastases from malignant melanoma. <i>British Journal of Surgery</i> , <b>2012</b> , 99, 821-30	5.3	78
78	A case of squamous cell carcinoma of the scalp after several synthetic hair grafts. <i>Aesthetic Plastic Surgery</i> , <b>2012</b> , 36, 649-52	2	4
77	Meyerson <sup>®</sup> phenomenon in a patient affected by high-risk melanoma under treatment with interferon- $\beta$ . <i>Melanoma Research</i> , <b>2012</b> , 22, 284-5	3.3	2
76	Overdose of Vinblastine in place of Vinorelbine during IGEV chemotherapy. <i>Immunopharmacology and Immunotoxicology</i> , <b>2012</b> , 34, 879-80	3.2	7
75	Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?. <i>Journal of Cancer Research and Therapeutics</i> , <b>2012</b> , 8, 619-25 <sup>1,2</sup>		6
74	Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6485-96	12.9	53
73	Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy. <i>Pigment Cell and Melanoma Research</i> , <b>2011</b> , 24, 728-30	4.5	11
72	A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 427-32	8.7	38
71	Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1816-21	8.7	44
70	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1712-1717	10.3	397
69	Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?. <i>Annals of Surgery</i> , <b>2010</b> , 252, 788-96	7.8	49
68	Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. <i>Archives of Surgery</i> , <b>2009</b> , 144, 247-54; discussion 254		85
67	Small molecules and targeted therapies in distant metastatic disease. <i>Annals of Oncology</i> , <b>2009</b> , 20 Suppl 6, vi35-40	10.3	61

66	Surgery and radiotherapy in the treatment of cutaneous melanoma. <i>Annals of Oncology</i> , <b>2009</b> , 20 Suppl 6, vi22-9	10.3	83
65	Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2009</b> , 671, 26-32	3.3	13
64	Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 1111-9	3.5	19
63	Anetoderma in cutaneous marginal-zone B-cell lymphoma. <i>Clinical and Experimental Dermatology</i> , <b>2009</b> , 34, e945-8	1.8	4
62	Bleomycin-based electrochemotherapy: clinical outcome from a single institution experience with 52 patients. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 191-9	3.1	209
61	IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. <i>Journal of Immunology</i> , <b>2009</b> , 182, 6562-8	5.3	263
60	9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy. <i>European Journal of Cancer, Supplement</i> , <b>2009</b> , 7, 581	1.6	2
59	9307 Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials. <i>European Journal of Cancer, Supplement</i> , <b>2009</b> , 7, 578	1.6	2
58	Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion. <i>Melanoma Research</i> , <b>2009</b> , 19, 193-4	3.3	
57	A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4546-4546 <sup>2,2</sup>	2.2	2
56	Primary subcutaneous B-cell lymphoma: case report and literature review. <i>Acta Dermato-Venereologica</i> , <b>2008</b> , 88, 151-4	2.2	6
55	Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high-dose interferon-alpha-2b adjuvant therapy for melanoma. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 675-8	5	6
54	TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 1218-23	3.1	15
53	Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 9045-9045	2.2	38
52	Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 68, 823-9	4	37
51	Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. <i>British Journal of Cancer</i> , <b>2007</b> , 96, 432-8	8.7	29
50	Results of esophagectomy for esophageal cancer in elderly patients: age has little influence on outcome and survival. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2007</b> , 133, 1186-92	1.5	109
49	Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 3243-50	3.1	64

48	Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. <i>BMC Cancer</i> , <b>2006</b> , 6, 44	4.8	18
47	Treatment of chemotherapy-induced oral mucositis with light-emitting diode. <i>Photomedicine and Laser Surgery</i> , <b>2006</b> , 24, 207-13		46
46	A gene expression signature associated with survival in metastatic melanoma. <i>Journal of Translational Medicine</i> , <b>2006</b> , 4, 50	8.5	82
45	Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. <i>Melanoma Research</i> , <b>2006</b> , 16, 317-23	3.3	10
44	Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 1550-2	8.7	4
43	Treatments of AIDS-related Kaposi's sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2005</b> , 53, 253-657		45
42	Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. <i>Acta Haematologica</i> , <b>2004</b> , 112, 141-7	2.7	9
41	Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1714-7	9.7	143
40	Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. <i>International Journal of Cancer</i> , <b>2004</b> , 111, 741-5	7.5	52
39	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 51, 171-89	7	18
38	Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. <i>Lung Cancer</i> , <b>2004</b> , 43, 83-91	5.9	51
37	Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. <i>Melanoma Research</i> , <b>2004</b> , 14, 295-9	3.3	16
36	Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. <i>Journal of Translational Medicine</i> , <b>2003</b> , 1, 13	8.5	8
35	Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. <i>European Journal of Cancer</i> , <b>2003</b> , 39, 1577-85	7.5	48
34	Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1600-7	2.2	99
33	Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. <i>Cancer</i> , <b>2002</b> , 95, 569-75	6.4	68
32	Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. <i>Journal of Immunology</i> , <b>2002</b> , 169, 4017-24	5.3	36
31	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1600-1607	2.2	60

30	Radiotherapy alone in the treatment of clinical stage I-IIA, nonbulky, Hodgkin disease: single-institution experience on 73 patients staged with lymphangiography and laparoscopy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2002</b> , 25, 149-52	2.7	0
29	Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. <i>Cancer</i> , <b>2001</b> , 91, 2165-2174	6.4	329
28	Elderly ovarian cancer: treatment with mitoxantrone-carboplatin. <i>Gynecologic Oncology</i> , <b>2001</b> , 80, 221-6	4.9	7
27	Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. <i>Melanoma Research</i> , <b>2001</b> , 11, 189-96	3.3	55
26	VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin lymphoma: results of a prospective randomized trial by the non-Hodgkin Lymphoma Cooperative Study Group. <i>Journal of Clinical Oncology</i> , <b>1998</b> , 16, 2796-802	2.2	184
25	First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. <i>Annals of Surgery</i> , <b>1997</b> , 226, 714-23; discussion 723-4	7.8	51
24	Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study. <i>European Journal of Cancer</i> , <b>1996</b> , 32A, 2064-9	7.5	18
23	Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin disease. <i>Annals of Oncology</i> , <b>1995</b> , 6, 173-9	10.3	2
22	Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. <i>Journal of the National Cancer Institute</i> , <b>1994</b> , 86, 265-72	9.7	350
21	Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. <i>European Journal of Cancer</i> , <b>1993</b> , 29A, 704-8	7.5	6
20	A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1993</b> , 16, 264-7	2.7	6
19	Secondary Leukemia following Treatment for Hodgkin Disease. <i>Tumori</i> , <b>1993</b> , 79, 103-107	1.7	8
18	Late relapses in Hodgkin disease: outcome of patients relapsing more than twelve months after primary chemotherapy. <i>Annals of Oncology</i> , <b>1993</b> , 4, 657-62	10.3	13
17	A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin lymphoma. <i>Annals of Oncology</i> , <b>1992</b> , 3, 833-7	10.3	31
16	Extramedullary plasmacytoma: clinical behaviour and response to treatment. <i>Annals of Oncology</i> , <b>1992</b> , 3, 51-7	10.3	55
15	Deflazacort and Fluoximesterone in Advanced, Pretreated Breast Cancer. <i>Tumori</i> , <b>1992</b> , 78, 266-269	1.7	
14	Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1992</b> , 30, 221-5	3.5	24
13	Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. <i>Cancer</i> , <b>1991</b> , 68, 975-80	6.4	14

12	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. <i>Cancer</i> , <b>1990</b> , 65, 2631-4	6.4	22
11	Leucovorin calcium enhancement of mucositis after continuous infusion fluorouracil and short infusion cisplatin. <i>Journal of Clinical Oncology</i> , <b>1989</b> , 7, 680-1	2.2	4
10	Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses. <i>Journal of Surgical Oncology</i> , <b>1988</b> , 4, 184-90		18
9	Peptichemio in pretreated patients with plasmacell neoplasms. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1986</b> , 22, 1053-8		6
8	Cisplatin plus Vindesine versus Cisplatin plus VP16 versus Doxorubicin plus Cytosan in Non-Small-Cell Carcinoma of the Lung. A Randomized Study. <i>Tumori</i> , <b>1986</b> , 72, 417-425	1.7	9
7	Lipid Bound Sialic Acid in Cancer Patients. <i>Tumori</i> , <b>1985</b> , 71, 127-133	1.7	9
6	Vindesine in Plasma Cell Tumors. <i>Tumori</i> , <b>1985</b> , 71, 533-536	1.7	1
5	Urinary Hydroxyproline in Multiple Myeloma: Correlation with Clinical Stages and Bone Disease. <i>Tumori</i> , <b>1984</b> , 70, 249-253	1.7	2
4	Cisplatin, bleomycin and methotrexate in the treatment of advanced oesophageal cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1984</b> , 20, 743-7		18
3	Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1983</b> , 19, 1345-51		25
2	Cis-Dichlorodiammineplatinum (II), VP 16-213, and Prednisone (Dvp Regimen) in the Treatment of Pretreated Advanced Malignant Lymphomas. <i>Tumori</i> , <b>1982</b> , 68, 515-518	1.7	1
1	Serum Copper Level in Non-Hodgkin's Lymphomas. <i>Tumori</i> , <b>1982</b> , 68, 57-62	1.7	3